1. <th id="ya0vw"><sup id="ya0vw"></sup></th>
      <pre id="ya0vw"><small id="ya0vw"><input id="ya0vw"></input></small></pre>
    2. <pre id="ya0vw"><small id="ya0vw"><p id="ya0vw"></p></small></pre>
      <strike id="ya0vw"></strike>
    3. <code id="ya0vw"></code>

      www.247cinema.cn 提示:

      本信息僅供醫學專業人士參考,如果您是醫學專業人士,請點擊確定后進入。 如果不是,請點擊取消。

      取消 確定

      Strive to enable biopharmaceuticals created and
      manufactured by China to benefit patients worldwide

      Overview of the international registration and marketing of 3SBio Group products

      At present, 3SBio products that are registered overseas include YISAIPU, TPIAO, EPIAO, Intefen and SEPO, etc. The registration has covered nearly 40 countries and regions around the world, with the business and customer scope basically covering all the developing countries. After years of hard work, these products have also been registered and listed in many countries.

      • Latin American region with Mexico, Colombia, Brazil, etc. being the centers
      • South Asia Region with India, Pakistan, Bangladesh and Sri Lanka being the centers
      • Southeast Asian region with Thailand, Indonesia, Philippines and Vietnam being centers
      • The Commonwealth of the Independent States (CIS) region with Russia, Belarus and Ukraine being centers
      • Middle Eastern & Northern Africa (MENA) region with Turkey and Egypt being centers

      In the future, 3SBio’s international business will focus on emerging markets or developing countries such as Brazil, Mexico, Colombia in Latin America, Indonesia, Philippines, Thailand in Southeast Asia, Russia, Ukraine, Uzbekistan in CIS, Turkey, Saudi Arabia, Egypt, Jordan, Morocco in Middle East and North Africa, India, Sri Lanka, Pakistan and Bangladesh in South Asia. It will promote the overseas distribution of EPO, TPO, Yisaipu and SEPO via out-licensing or partnerships with local agents. At the same time, the Company will actively participate in the development of overseas pharmaceutical industries and contribute to the improvement of medical capabilities in developing countries through technology transfers, local joint ventures, capital contribution with technologies, and mergers and acquisitions.

      Clinical experience (important internationally published papers)

      • Application of Etanar? Therapy in Patients with Rheumatoid Arthritis

        Published at the 74th Annual Scientific Meeting of the American College of Rheumatology (ACR), Atlanta, Georgia, USA, in November 10, 2010.

        Abstract 1811. In the “real life” environment, the 20-week efficacy and safety analysis was conducted in the 110 patients who received Etanar? (25 mg, subcutaneous injection, twice a week) in combination with multiple DMARD anti-RA treatment for a long time.

      • ETANAR - Generic drug YISAIPU is as effective as adalimumab and infliximab in treating a group of patients with rheumatoid arthritis

        This article was published as a poster in EULARL 2015 (Rome, Italy) (P. Santos-Moreno et al. Ann Rheum Dis 2015; 74:789-790).

        The descriptive cross-sectional study included 158 RA patients who visited at least 6 rheumatologists within the past 24 months, and respectively received adalimumab (61 (38.6%), infliximab (35 (22.2 %) and YISAIPU biosimilar products (62 (39.2%) (Etanar? CP Guojian Pharmaceutical Co., Ltd. (China)).

      • Clinical Outcomes of Etanar - a New Biotype of rhTNFR:Fc in Colombian Patients with Rheumatoid Arthritis

        (PISantos-Moreno, G. Sánchez, D. Gómez, C. Castro. Clinical and Experimental Rheumatology, 2015; 33: 858-862.) A multicenter observational cohort study evaluated the clinical reactions at the 12th month in 105 RA patients treated with Etanar (rhTNFR:Fc) and the incidence of the adverse reactions was recorded.

      • Comparison of the direct effects of three anti-tumor necrosis factor biologics in the cohort of patients with rheumatoid arthritis

        (Pedro Santos-Moreno, Guillermo Sánchez, Danny Gómez. et al; JCR-Journal of Clinical Rheumatology, 2016; 22 (2):57-62) The observational retrospective cohort study compared the clinical reactions at 36 months after treatment in 307 RA patients who received YISAIPU (Etanar?), infliximab (Remecade?) or adalimumab (Humira?) and evaluated the adverse events.

      International Business Department

      Address: No. 399 Libing Road, Zhangjiang Hi-Tech Park, Shanghai, China. Post code: 201203

      Email Address : international@3sbio.com

      Tel: +86-21-50791399